LBF20207TX02: Difference between revisions

Line 15: Line 15:
|NMR Spectra=<SUP><FONT SIZE=-1>1</FONT></SUP>H-NMR(CDCl<SUB><FONT SIZE=-1>3</FONT></SUB>) : <FONT FACE="Symbol">d</FONT> 5.86(m, 1H, 14-CH), 5.72(m, 1H, 13-CH), 5.46(m, 2H, 5,6-CH), 5.35 and 5.23(m, 1H, 11-CH), 4.41(m, 1H, 12-CH), 4.22(m, 1H, 15-CH), 4.11(m, 1H, 9-CH), 2.35(t, 2H, 2-CH<SUB><FONT SIZE=-1>2</FONT></SUB>), 0.89(m, 3H, 20-CH<SUB><FONT SIZE=-1>3</FONT></SUB>) [[Reference:Kotovych_G:Aarts_GHM:,Can. J. Chem.,1980,58,1111|{{RelationTable/GetFirstAuthor|Reference:Kotovych_G:Aarts_GHM:,Can. J. Chem.,1980,58,1111}}]]
|NMR Spectra=<SUP><FONT SIZE=-1>1</FONT></SUP>H-NMR(CDCl<SUB><FONT SIZE=-1>3</FONT></SUB>) : <FONT FACE="Symbol">d</FONT> 5.86(m, 1H, 14-CH), 5.72(m, 1H, 13-CH), 5.46(m, 2H, 5,6-CH), 5.35 and 5.23(m, 1H, 11-CH), 4.41(m, 1H, 12-CH), 4.22(m, 1H, 15-CH), 4.11(m, 1H, 9-CH), 2.35(t, 2H, 2-CH<SUB><FONT SIZE=-1>2</FONT></SUB>), 0.89(m, 3H, 20-CH<SUB><FONT SIZE=-1>3</FONT></SUB>) [[Reference:Kotovych_G:Aarts_GHM:,Can. J. Chem.,1980,58,1111|{{RelationTable/GetFirstAuthor|Reference:Kotovych_G:Aarts_GHM:,Can. J. Chem.,1980,58,1111}}]]
|Source=Thromboxane B2 as a stable degradation product of bioactive but unstable thromboxane A2 is detected in the tissue where thromboxane A2 is produced [[Reference:Moncada_S:Vane_JR:,Pharmacol. Rev.,1978,30,293|{{RelationTable/GetFirstAuthor|Reference:Moncada_S:Vane_JR:,Pharmacol. Rev.,1978,30,293}}]];>.
|Source=Thromboxane B2 as a stable degradation product of bioactive but unstable thromboxane A2 is detected in the tissue where thromboxane A2 is produced [[Reference:Moncada_S:Vane_JR:,Pharmacol. Rev.,1978,30,293|{{RelationTable/GetFirstAuthor|Reference:Moncada_S:Vane_JR:,Pharmacol. Rev.,1978,30,293}}]];>.
|Chemical Synthesis=[[Reference:Hanessian_S:Lavallee_P:,Can. J. Chem.,1977,55,562|{{RelationTable/GetFirstAuthor|Reference:Hanessian_S:Lavallee_P:,Can. J. Chem.,1977,55,562}}]];> {{Image200|XPR2101FT0001.gif}}
|Chemical Synthesis=[[Reference:Hanessian_S:Lavallee_P:,Can. J. Chem.,1977,55,562|{{RelationTable/GetFirstAuthor|Reference:Hanessian_S:Lavallee_P:,Can. J. Chem.,1977,55,562}}]];> {{Image200|LBF20207TX02FT0001.gif}}
|Metabolism=The major urinary metabolite of tromboxane B2 is 2,3-dinor-thromboxane B2 [[Reference:Kindahl_H:,Prostaglandins,1977,13,619|{{RelationTable/GetFirstAuthor|Reference:Kindahl_H:,Prostaglandins,1977,13,619}}]];>, and 11-dehydro-thromboxane B2 is known as a suitble parameter for monitoring thromboxane production in human [[Reference:Westlund_P:Granstrom_E:Kumlin_M:Nordenstrom_A:,Prostaglandins,1986,31,929|{{RelationTable/GetFirstAuthor|Reference:Westlund_P:Granstrom_E:Kumlin_M:Nordenstrom_A:,Prostaglandins,1986,31,929}}]];>. 11-Hydroxythromboxane B2 dehydrogenase responsible for the 11-dehydro-thromboxane B2 production was identified as cytosolic aldehyde dehydrogenase [[Reference:Westlund_P:Fylling_AC:Cederlund_E:Jornvall_H:,FEBS Lett.,1994,345,99|{{RelationTable/GetFirstAuthor|Reference:Westlund_P:Fylling_AC:Cederlund_E:Jornvall_H:,FEBS Lett.,1994,345,99}}]];>.
|Metabolism=The major urinary metabolite of tromboxane B2 is 2,3-dinor-thromboxane B2 [[Reference:Kindahl_H:,Prostaglandins,1977,13,619|{{RelationTable/GetFirstAuthor|Reference:Kindahl_H:,Prostaglandins,1977,13,619}}]];>, and 11-dehydro-thromboxane B2 is known as a suitble parameter for monitoring thromboxane production in human [[Reference:Westlund_P:Granstrom_E:Kumlin_M:Nordenstrom_A:,Prostaglandins,1986,31,929|{{RelationTable/GetFirstAuthor|Reference:Westlund_P:Granstrom_E:Kumlin_M:Nordenstrom_A:,Prostaglandins,1986,31,929}}]];>. 11-Hydroxythromboxane B2 dehydrogenase responsible for the 11-dehydro-thromboxane B2 production was identified as cytosolic aldehyde dehydrogenase [[Reference:Westlund_P:Fylling_AC:Cederlund_E:Jornvall_H:,FEBS Lett.,1994,345,99|{{RelationTable/GetFirstAuthor|Reference:Westlund_P:Fylling_AC:Cederlund_E:Jornvall_H:,FEBS Lett.,1994,345,99}}]];>.
}}
}}


{{Lipid/Footer}}
{{Lipid/Footer}}

Revision as of 10:00, 25 November 2009

LipidBank Top
(トップ)
Fatty acid
(脂肪酸)
Glycerolipid
(グリセロ脂質)
Sphingolipid
(スフィンゴ脂質)
Journals
(雑誌一覧)
How to edit
(ページの書き方)


Upper classes: LB LBF



THROMBOXANE B2
LBF20207TX02.png
Structural Information
7- [ Tetrahydro-4 (S) ,6-dihydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) -2H-pyran-3 (S) -yl ] -5 (Z) -heptenoic acid
  • THROMBOXANE B2
  • 7- [ Tetrahydro-4 (S) ,6-dihydroxy-2 (R) - (3 (S) -hydroxy-1 (E) -octenyl) -2H-pyran-3 (S) -yl ] -5 (Z) -heptenoic acid
Formula C20H34O6
Exact Mass 370.23553882
Average Mass 370.48036
SMILES C(CC[C@H](O)C=C[C@@H](O1)[C@@H]([C@@H](CC1O)O)CC=CCCCC(O)=O)CC
Physicochemical Information
95-96°C Hanessian_S et al.
ETHYL ACETATE
Thromboxane B2 as a stable degradation product of bioactive but unstable thromboxane A2 is detected in the tissue where thromboxane A2 is produced Moncada_S et al.;>.
Hanessian_S et al.;>
LBF20207TX02FT0001.gif
The major urinary metabolite of tromboxane B2 is 2,3-dinor-thromboxane B2 Kindahl_H ;>, and 11-dehydro-thromboxane B2 is known as a suitble parameter for monitoring thromboxane production in human Westlund_P et al.;>. 11-Hydroxythromboxane B2 dehydrogenase responsible for the 11-dehydro-thromboxane B2 production was identified as cytosolic aldehyde dehydrogenase Westlund_P et al.;>.
Spectral Information
Mass Spectra m/e 335, 317 HanessianSet al.
UV Spectra
IR Spectra FILM: n 3380, 1705cm-1 HanessianSet al.
NMR Spectra 1H-NMR(CDCl3) : d 5.86(m, 1H, 14-CH), 5.72(m, 1H, 13-CH), 5.46(m, 2H, 5,6-CH), 5.35 and 5.23(m, 1H, 11-CH), 4.41(m, 1H, 12-CH), 4.22(m, 1H, 15-CH), 4.11(m, 1H, 9-CH), 2.35(t, 2H, 2-CH2), 0.89(m, 3H, 20-CH3) KotovychGet al.
Other Spectra
Chromatograms
Reported Metabolites, References
Biospecies ID Compound Name Reference Comment
n.a. LBF20207TX02 See above. Hanessian_S et al. 1977
n.a. LBF20207TX02 See above. Kelly_RW et al. 1976
n.a. LBF20207TX02 See above. Kindahl_H 1977
n.a. LBF20207TX02 See above. Kotovych_G et al. 1980
n.a. LBF20207TX02 See above. Moncada_S et al. 1978
n.a. LBF20207TX02 See above. Westlund_P et al. 1994
n.a. LBF20207TX02 See above. Westlund_P et al. 1986